Given the unique products OSX have in their portfolio, it is an...

Given the unique products OSX have in their portfolio, it is an attractive proposition for a takeover. However, since the company has not been able to make sizeable/ noteworthy inroads into the medical market, a potential buyer may not bid aggressively. Even if OSX gets an offer 50% higher than the current market price, it would be around 48cents per share. At that price, unfortunately most retail investors will not still break even.

At current levels, I am undecided if I want to average out further!